Since its very public outing via the media much research has been carried out around it's detection.
Among the research Dr. John Connolly at the University of Strathclyde, together with colleagues from the Scottish National Blood Transfusion Service, Roslin Institute and the University of Edinburgh, have developed several monoclonal antibodies (mAbs) that distinguish disease-associated, abnormal prion protein (PrPSc) from the normal cellular form (PrPC).
Cases of variant CJD infection through blood transfusion have to date been rare but the threat of person-to-person transmission of vCJD remains. Thus a rapid and reliable method for detecting the abnormal prion protein in blood samples is needed.
To meet this need, the team have developed a novel panel of antibodies. And some of these can distinguish between normal and vCJD associated forms of prion protein in immunoprecipitation experiments.